Your binder contains too many pages, the maximum is 40.
We are unable to add this page to your binder, please try again later.
This page has been added to your binder.
June 4, 2012
NEW YORK, June 4, 2012 — Covington advised UCB S.A. in the acquisition of a majority interest in Meizler Biopharma, S.A., a Brazilian pharmaceutical company that commercializes a portfolio of in-licensed specialty products.
The transaction agreements foresee performance related milestone payments in the coming years as well as an option to purchase the remaining 49 percent of the company. The parties have agreed not to disclose further details pertaining to financial elements of the transaction.
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
The Covington team included partner Rubén Kraiem, Jonas Marson, Richard Kruger and Paula Domingos*. UCB was also advised in this transaction by Vieira Rezende Barbosa & Guerreiro Advogados and, on certain regulatory matters, by Portugal Ribeiro & Navarro Prado.
*Admitted to the California bar; not admitted to practice in New York.